No Difference in the Phenotypic Expression of Frailty Among Elderly Patients Recently Diagnosed with Cancer Vs Cancer Free Patients
Overview
Nutritional Sciences
Authors
Affiliations
Objectives: To examine frailty determinants differences in patients with a recent diagnosis of cancer compared to non-cancer patients among older adult. Revealing those differences will allow us to individualize the exact frailty management in those patients diagnosed with cancer.
Design: This is an observational cross-sectional, monocentric study.
Setting: Patients were evaluated at the Geriatric Frailty Clinic (GFC), in the Toulouse University Hospital, France, between October 2011 and February 2016.
Participants: 1996 patients aged 65 and older were included (1578 patients without cancer and 418 patients with solid and hematological cancer recently diagnosed).
Measurements: Frailty was established according to the frailty phenotype. The frailty phenotype measures five components of frailty: weight loss, exhaustion, low physical activity, weakness and slow gait. Frailty phenotype was categorized as robust, pre-frail and frail.
Results: In a multinomial logistic regression, cancer, compared to the non-cancer group, is not associated with an increased likelihood of being classified as pre frail (RRR 0.9, 95% CI [0.5 ; 1.6 ], p 0.9) or frail (RRR 1.2, 95% CI [0.7 ; 2.0], p 0.4) rather than robust. When considering each Fried criterion, a significant higher odd of weight loss was observed in older patients with cancer compared to the non-cancer patients (OR 2.3, 95% CI [1.8; 3.0], p <0.001) but no statistically significant differences was found among the four other Fried criteria. Sensitivity analysis on the frailty index showed that cancer was not associated with a higher FI score compared to non-cancer (β 0.002, 95%CI [-0.009; 0.01], p 0.6).
Conclusion: In this real-life study evaluating elderly patients with and without cancer, we didn't confirm our hypothesis, in fact we found that cancer was not associated with frailty severity using both a phenotypic model and a deficit accumulation approach. Cancer may contribute, at least additively, to the development of frailty, like any other comorbidity, rather than a global underlying condition of vulnerability.
Frailty in chronic myeloid leukemia: evidence from 2016-2018 Nationwide Inpatient Sample of the US.
Huan-Tze L, Yun-Ru L, Kuan-Der L, Huey-En T BMC Geriatr. 2023; 23(1):334.
PMID: 37254068 PMC: 10228104. DOI: 10.1186/s12877-023-03962-7.
Onishchenko D, Rubin D, van Horne J, Ward R, Chattopadhyay I J Am Heart Assoc. 2022; 11(15):e023745.
PMID: 35904198 PMC: 9375497. DOI: 10.1161/JAHA.121.023745.
Muzyka M, Tagliafico L, Serafini G, Baiardini I, Braido F, Nencioni A Cancers (Basel). 2022; 14(1).
PMID: 35008421 PMC: 8796027. DOI: 10.3390/cancers14010258.